


Accepted Manuscript

Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design



Takaomi Kessoku, Kento Imajo, Takashi Kobayashi, Yasushi Honda, Takayuki Kato, Yuji Ogawa, Wataru Tomeno, Shingo Kato, Takuma Higurashi, Masato Yoneda, Hiroyuki Kirikoshi, Kazuki Kubota, Masataka Taguri, Takeharu Yamanaka, Haruki Usuda, Koichiro Wada, Satoru Saito, Atsushi Nakajima

PII: S1551-7144(18)30053-3
DOI: doi:[10.1016/j.cct.2018.04.002](https://doi.org/10.1016/j.cct.2018.04.002)
Reference: CONCLI 1737
To appear in: *Contemporary Clinical Trials*
Received date: 27 January 2018
Revised date: 29 March 2018
Accepted date: 3 April 2018

Please cite this article as: Takaomi Kessoku, Kento Imajo, Takashi Kobayashi, Yasushi Honda, Takayuki Kato, Yuji Ogawa, Wataru Tomeno, Shingo Kato, Takuma Higurashi, Masato Yoneda, Hiroyuki Kirikoshi, Kazuki Kubota, Masataka Taguri, Takeharu Yamanaka, Haruki Usuda, Koichiro Wada, Satoru Saito, Atsushi Nakajima , Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Concli(2018), doi:[10.1016/j.cct.2018.04.002](https://doi.org/10.1016/j.cct.2018.04.002)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: the LUBIPRONE, double-blind, randomised, placebo-controlled study design

Takaomi Kessoku¹, Kento Imajo¹, Takashi Kobayashi¹, Yasushi Honda¹, Takayuki Kato¹, Yuji Ogawa¹, Wataru Tomeno¹, Shingo Kato¹, Takuma Higurashi¹, Masato Yoneda¹, Hiroyuki Kirikoshi², Kazuki Kubota³, Masataka Taguri³, Takeharu Yamanaka³, Haruki Usuda⁴, Koichiro Wada⁴, Satoru Saito¹, Atsushi Nakajima^{1*}

¹ Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan

² Clinical Laboratory Department, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan

³ Department of Biostatistics, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan

⁴ Department of Pharmacology, Shimane University School of Medicine, 89-1, Enyacho, Izumo, Shimane, 693-8501, Japan

Author email addresses

Download English Version:

<https://daneshyari.com/en/article/8757514>

Download Persian Version:

<https://daneshyari.com/article/8757514>

[Daneshyari.com](https://daneshyari.com)